Closure of Patent Foramen Ovale for Pardoxical Emboli: Intermediate-Term Risk of Recurrent Neurological Events Following Transcatheter Device Placement
J Am Coll Cardiol 35:1311-1316, Hung,J.,et al, 2000
Infective Endocarditis at Autopsy
Medicine 91:152-164, Fernandez Guerrero,M.L.,et al, 2012
Valvular Heart Disease and the Use of Dopamine Agonists for Parkinsons Disease
NEJM 356:39-46, Zanettini,R.,et al, 2007
Dopamine Agonists and the Risk of Cardiac Valve Regurgitation
NEJM 356:29-38, Schade,R.,et al, 2007
Cardiac Valve Regurgitation With Pergolide Compared With Nonergot Agonsits in Parkinson Disease
Arch Neurol 64:377-380, Dewey,R.B.,Jr, et al, 2007
Treatment of Parkinson's Disease with Pergolide and Relation to Restrictive Valvular Heart Disease
Lancet 363:1179-1183, Van Camp,G.,et al, 2004
Incidence and Clinical Course of Thrombus Formation on Atrial Septal Defect and Patent Foramen Ovale Closure Devices in 1,000 Consecutive Patients
J Am Coll Cardiol 43:302-309, Krumsdorf,U.,et al, 2004
Incidence of Thrombus Formation on the CardioSEAL and the Amplatzer Interatrial Closure Devices
Am J Cardiol 93:426-431, Anzai,H.,et al, 2004
Valve Disease Associated with Ergot Alkaloid Use:Echocardiographic and Pathologic Correlations
Ann Int Med 117:50-52, Redfield,M.M.,et al, 1992